https://www.selleckchem.com/pr....oducts/NVP-AUY922.ht
Despite pre-clinical evidence of efficacy, clinical translation has resulted into disappointingly modest efficacy. #link# Poor pharmacokinetic and physiochemical properties of cyclic dinucleotides are key barriers to the development of STING agonists, most of which require intra-tumoral dosing. link2 Development of systemically administered non-nucleotidyl STING agonists, or conjugation with liposomes, polymers and hydrogels may overcome pharmacokinetic limitations and improve drug delivery. In this review, we summarise the body of e
Like
Comment
Share
